%A Damoiseaux,Jan %D 2021 %J Frontiers in Immunology %C %F %G English %K Vasculitis,proteinase 3 (PR3),Myeloperoxidase (MPO),Standardisation,Harmonisation %Q %R 10.3389/fimmu.2021.656796 %W %L %M %P %7 %8 2021-March-16 %9 Review %# %! ANCA testing in vasculitis %* %< %T ANCA Testing in Clinical Practice: From Implementation to Quality Control and Harmonization %U https://www.frontiersin.org/articles/10.3389/fimmu.2021.656796 %V 12 %0 JOURNAL ARTICLE %@ 1664-3224 %X Analyses for the presence of anti-neutrophil cytoplasmic antibodies (ANCA) are important in the diagnostic work-up of patients with small vessel vasculitis. Since current immuno-assays are predominantly designed for diagnosis of patients with ANCA-associated vasculitis (AAV), implementation in routine clinical practice, internal and external quality control, and harmonization are focused on this particular use. However, ANCA testing may also be relevant for monitoring therapy efficacy and for predicting a clinical relapse in AAV patients, and even for diagnostic purposes in other clinical situations. In the current review, the topics of implementation, quality control, and standardization vs. harmonization are discussed while taking into account the different applications of the ANCA assays in the context of AAV.